



Fig. S6. EV counts for patients with different types of pancreatic diseases. The total EV counts were measured for patient cohorts ($n = 103$) including i) PDAC without treatment ($n = 22$), ii) PDAC treated with neoadjuvant regimen ($n = 24$), iii) IPMN ($n = 13$), iv) other GI cancers mimicking the symptoms of pancreatico-duodenal cancers ($n = 11$), v) pancreatic neuroendocrine tumors ($n = 12$), vi) pancreatitis ($n = 8$), vii) benign cystic tumors, and ($n = 5$) and ix) age-matched controls ($n = 8$).